Biocad India

Biocad India Private Limited is the Indian subsidiary of JSC BIOCAD, a leading international biotechnology company based in Russia. Established in 2012 and headquartered in Bengaluru, the company focuses on the registration, clinical development, marketing, and distribution of BIOCAD's advanced biosimilars and original biologic therapies in the Indian market. Its portfolio includes approved biosimilars such as Acellbia (rituximab), Herticad (trastuzumab), Avegra (bevacizumab), and Extimia (empegfilgrastim), targeting critical therapeutic areas like oncology, hematology, and autoimmune diseases. Biocad India operates as a commercial entity, leveraging its parent company's robust R&D and manufacturing capabilities to provide affordable, high-quality biologic treatments to patients across India.